BIIB Biogen Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 17
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: 38
Relative Profitability: Rel. Profitability: 52

EPS in 2026 (TTM): $5.68

Last Report Period Date: Jun 30, 2026

As of August this year, based on Biogen's most recent financial report, the company's trailing twelve months EPS is $5.68. During 2025, BIIB reported a per-share earnings of $8.83, which shows a decrease compared to the EPS of $11.21 recorded in 2024. Biogen's EPS for the quarterly period ending on Jun 30, 2026 came in at $0.66.

BIIB earnings history

Historical annual and quarterly earnings per share (EPS) data for Biogen
EPS (TTM)
$5.68
EPS Growth YoY (Quarterly)
-84.8%
EPS (Quarterly)
$0.66
EPS Growth (Quarterly)
-69.6%

The yearly earnings per share during 2025 was $8.83, a decrease of 21.2% compared to $11.21 recorded in 2024. Over the quarter ending Jun 30, 2026, the earnings per share came in at $0.66, reflecting a 84.8% decline compared to the same quarter a year earlier. As of June 2026, the TTM EPS is $5.68. During 2024, the annual earnings per share was $11.21, representing an increase of 39.8% compared to 2023.

BIIB earnings chart

BIIB EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-84.8%
EPS growth YoY
-21.2%
EPS growth 3Y avg
-25%
EPS growth 5Y avg
-18.7%

Over the past 12 months, Biogen has recorded an earnings per share growth rate of -84.8% (YoY, quarterly). Over an extended period, the company recorded an average EPS annual growth rate of -25% per year for the last 3 years. In the last five years, the company had an average annual EPS growth of -18.7%. A ten-year view shows that BIIB has seen an average earnings per share growth of -5.4% per year.

BIIB Earnings Waterfall

Breakdown of revenue, profit and net income for Biogen

BIIB Earnings vs Peers

What are the earnings of BIIB compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
GILD Gilead Sciences Inc 17.45 1,700% 23.2% 132.8%
PFE Pfizer Inc 19.07 -3.5% -37.4% -3.7%
QGEN Qiagen NV 22.7 415.8% 1.8% 3.9%
AMGN AMGEN Inc 26.39 88.1% 5.6% 2.9%
JNJ Johnson & Johnson 28.89 90.6% 17.7% 14.8%
BIIB Biogen Inc 35.69 -21.2% -25% -18.7%
ILMN Illumina Inc 38.07 171.1% N/A 4.1%
BIO Bio-Rad Laboratories Inc - Class A 56.95 142.6% N/A -26.3%
ABBV Abbvie Inc 121.21 -1.3% -29.1% -2.8%

All data is based on quarterly TTM periods, unless otherwise specified.